Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Multiple sclerosis: TNF revisited, with promise

Nature Medicine volume 1, pages 211–214 (1995)Cite this article

The antidepressant drug rolipram inhibits tumor necrosis factor-α. This may make it an effective treatment for multiple sclerosis (pages 244–248).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sommer, N. et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med. 1, 244–248 (1995).

    Article  CAS  Google Scholar 

  2. O'Garra, A. & Murphy, K. T-cell subsets in autoimmunity. Curr. Opin. Immun. 6, 458–466 (1994).

    Article  CAS  Google Scholar 

  3. Raine, C.S. Demyelinating diseases. In Textbook of Neuropathology, (R.L. Davis, & D.M. Robertson, eds) 535–620 (Williams & Wilkins, Baltimore, 1990).

    Google Scholar 

  4. Raine, C.S. Morphology of myelin and myelination in Myelin (P. Morell, ed.) 1–50 (Plenum, New York, 1984).

    Google Scholar 

  5. Brosnan, C.F., Cammer, W., Norton, W.T. & Bloom, B.R. Proteinase inhibitors suppress the development of experimental autoimmune encephalomyelitis. Nature 285, 235–237 (1980).

    Article  CAS  Google Scholar 

  6. Selmaj, K.W. & Raine, C.S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro . Ann. Neurol. 23, 339–346 (1988).

    Article  CAS  Google Scholar 

  7. Selmaj, K.W., Farooq, M., Norton, W.T., Raine, C.S. & Brosnan, C.F. Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J. Immun. 147, 129–135 (1990).

    Google Scholar 

  8. Selmaj, K.W., Raine, C.S., Farooq, M., Norton, W.T. & Brosnan, C.F. Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. J. Immun. 147, 1522–1529 (1991).

    CAS  PubMed  Google Scholar 

  9. Ruddle, N.H. & Waksman, B.H. Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. Part 1. Characterization of the phenomenon. J. exp. Med. 128, 1237–1254 (1968).

    Article  CAS  Google Scholar 

  10. Ruddle, N.H. et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. exp. Med. 172, 1193–1200 (1990).

    Article  CAS  Google Scholar 

  11. Selmaj, K.W., Raine, C.S. & Cross, A.H. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol. 30, 694–700 (1991).

    Article  CAS  Google Scholar 

  12. Hofman, F.M., Hinton, D.R., Johnson, K. & Merrill, J.E. Tumor necrosis factor identified in multiple sclerosis brain. J. exp. Med. 170, 607–612 (1989).

    Article  CAS  Google Scholar 

  13. Selmaj, K.W., Raine, C.S., Cannella, B. & Brosnan, C.F. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. clin. Invest. 87, 949–954 (1991).

    Article  CAS  Google Scholar 

  14. Sharief, M.K. & Hentges, R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. New. Engl. J. Med. 325, 467–472 (1991).

    Article  CAS  Google Scholar 

  15. Tsukada, N., Matsuda, M., Miyagi, K. & Yanagisawa, N. Increased levels of intercellular adhesion molecule (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology 43, 2679–2682 (1993).

    Article  CAS  Google Scholar 

  16. Monastra, G., Cross, A.H., Bruni, A. & Raine, C.S. Phosphatidylserine, a putative inhibitor of tumor necrosis factor, prevents autoimmune demyelination. Neurology 43, 153–163 (1993).

    Article  CAS  Google Scholar 

  17. Baker, D., Butler, D., Scallon, B.J., O'Neill, J.K., Turk, J.L. & Feldmann, M. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur. J. Immun. 24, 2040–2048 (1994).

    Article  CAS  Google Scholar 

  18. Selmaj, K., Papierz, W., Glabinski, A. & Kohno, T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor 1. J. Neuroimmun. (in the press).

  19. Genain, C.P. et al. Prevention of autoimmune demyelination in non-human cAMP-specific phosphodiesterase inhibitor. Proc. natn. Acad. Sci. U.S.A. (in the press).

  20. Massacesi, L., Genain, C.P., Lee-Paritz, D., Letvin, N.L., Canfield, D. & Hauser, S.L. Actively and passively induced experimental autoimmune encephalomyelitis in common marmosets: A new model for multiple sclerosis. Ann. Neurol, (in the press).

  21. Jacobs, C.A. et al. Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor. J. Immun. 146, 2983–2989 (1991).

    CAS  PubMed  Google Scholar 

  22. Racke, M.K. et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. exp. Med. 180, 1961–1966 (1994).

    Article  CAS  Google Scholar 

  23. Rott, O., Fleischer, B. & Cash, E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur. J. Immun. 24, 1434–1440 (1994).

    Article  CAS  Google Scholar 

  24. Leonard, J.P., Waldburger, K.E. & Goldman, S.J. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. exp. Med. 181, 381–386 (1995).

    Article  CAS  Google Scholar 

  25. Billiau, A. et al. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-γ. J. Immun. 140, 1506–1510 (1988).

    CAS  PubMed  Google Scholar 

  26. Racke, M.K., Dhib-Jalbut, S., Cannella, B., Albert, P.S., Raine, C.S. & McFarlin, D.E. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J. Immun. 146, 3012–3017 (1991).

    CAS  PubMed  Google Scholar 

  27. Johns, L.D., Flanders, K.C., Ranhes, G.E. & Sriram, S. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-β 1. J. Immun. 147, 1792–1796 (1991).

    CAS  PubMed  Google Scholar 

  28. Kuruvilla, A.P., Shah, R., Hochwald, G.M., Liggitt, H.D., Palladino, M.A. & Thorbecke, G.I. Protective effect of transforming growth factor-β 1 on experimental autoimmune diseases in mice. Proc. natn. Acad. Sci. U.S.A. 88, 2918–2921 (1991).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pathology (Neuropathology), Neurology and Neuroscience, and the Rose F. Kennedy, Center for Research in Mental Retardation and Human Development, Albert Einstein, College of Medicine, Bronx, New York, 10461, USA

    Cedric S. Raine

Authors
  1. Cedric S. Raine
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raine, C. Multiple sclerosis: TNF revisited, with promise. Nat Med 1, 211–214 (1995). https://doi.org/10.1038/nm0395-211

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0395-211

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing